Fred Hutchinson Cancer Research Center (Seattle) begins Ceprate trial:
This article was originally published in Clinica
Executive Summary
The Fred Hutchinson Cancer Research Center (Seattle) has begun a pilot clinical trial of CellPro's stem cell separation system, Ceprate SC, in chronic lymphocytic leukaemia. The system is already in Phase II trials in multiple myeloma patients at 15 sites throughout North America (see Clinica No 638, p 19).
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.